{"entity":{"id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","aka":[],"tldr":"A phase 2 trial of nuzefatide pevedotin (BT5528) in pancreatic ductal adenocarcinoma, run by BicycleTx Limited, now recruiting.","summary":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 2 interventional study registered as NCT07450859 by BicycleTx Limited, with 39 participants planned, started 2026-03-05 and due to reach its primary completion in 2029-03. Interventions recorded: nuzefatide pevedotin (BT5528).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07450859","url":"https://clinicaltrials.gov/study/NCT07450859"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bicycle-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07450859","phase":"2","setting":"A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","sponsor":"BicycleTx Limited","started":"2026-03-05","startedType":"actual","enrolled":39,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07450859/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/"}]}}